An experimental drug now in clinical trials as a cancer treatment could help boost the power of first-line tuberculosis (TB) treatments by helping infected cells die a gentler death, Johns Hopkins Medicine investigators report, based on mouse-model research of the lung-damaging disease. Findings from the study, published in Nature Communications, could lead to more effective and less onerous therapies that reduce lung damage in TB survivors. It could also prevent lung dysfunction long after treatment completion, which is increasingly recognized as post-TB lung disease that affects tens of millions of TB patients.
This article was originally published on MedicalXpress.com
